Citations

Clear

4207 citation(s) found for "Chen, Yu".

Statins are rarely prescribed for incidentally discovered covert cerebrovascular disease: a retrospective cohort in a large electronic health record (EHR) identified using natural language processing
Leung, Lester Y. , Puttock, Eric J. , Kallmes, David F. , Chen, Wansu , Kent, David M. , Luetmer, Patrick, Kent, David M , Luetmer, Patrick H. , Fu, Sunyang , Zheng, Chengyi , Liu, Hongfang

Mayo Clinic

BMJ Neurology Open | November 11, 2024 | Volume: 6 | Issue: 2 | Pages: e000855

10.1136/bmjno-2024-000855 | PMID 39534403 Get It

Introduction While incidentally discovered covert cerebrovascular diseases (id-CCD) are associated with future stroke, it is not known if patients with id-CCD are prescribed statins. Methods Patients age ≥50 with id-CCD on neuroimaging from 2009 to 2019 with no prior ischaemic stroke, transient ischaemic attack or dementia were identified using natural language processing in a large real-world cohort. Robust Poisson multivariable regression was used to assess statin prescription among patients without prior statins. Results Among 2 41 050 patients, 74 975 patients (31.1%; 4.7% with covert brain infarcts (CBI); 29.0% with white matter disease (WMD)) had id-CCD. 53.5% (95% CI 53.2 to 53.9%) were not on statins within 6 months prior to the scan. Of those, 12.0% (95% CI 11.7 to 12.3%) were prescribed statins in the next 6 months compared with 9.3% (95% CI 9.1 to 9.4%) in those without CCD, a 2.7% (95% CI 2.4 to 3.1%) absolute increase in statin prescription for those with id-CCD. In adjusted analyses, the presence of id-CCD was only associated with minor increases in statin prescription (CBI or WMD (risk ratio (RR) 1.09, 95% CI 1.05 to 1.13), CBI alone (RR 1.34, 95% CI 1.21 to 1.47), WMD alone (RR 1.05, 95% CI 1.01 to 1.09), and CBI and WMD (RR 1.23, 95% CI 1.12 to 1.35)). Discussion Identification of id-CCD is not associated with substantial changes in statin prescription in routine clinical practice.
BIOM-16. A TARGETED GENE EXPRESSION BIOMARKER PREDICTS LOW GRADE MENINGIOMA RECURRENCE AND OVERALL SURVIVAL
Raleigh, David R. , Nguyen, Minh, Morshed, Ramin A. , Youngblood, Mark W. , Perlow, Haley K. , Lucas, Calixto‐Hope G. , Patel, Akash J. , Palmer, Joshua D. , McCortney, Kathleen , Horbinski, Craig , Magill, Stephen T. , Chen, William C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii22-viii22

10.1093/neuonc/noae165.0089 Get It

Abstract Targeted gene expression profiling improves risk stratification for meningiomas, but the utility of this approach for low grade meningiomas is incompletely understood. To address this, 466 meningiomas that were initially used to validate a 34-gene expression biomarker were combined with 270 previously unpublished samples for an analysis of biomarker performance in newly diagnosed (n=691) or recurrent (n=45) WHO grade 1 meningiomas treated with gross total (GTR) or subtotal resection (STR), and newly diagnosed WHO grade 2 meningiomas treated with GTR. Prediction of local freedom from recurrence (LFFR) or overall survival (OS) was measured using Cox proportional hazards models and the Kaplan-Meier method. The cohort included 736 patients, 69.4% female, with a median age at diagnosis of 58 years. There were 635 WHO grade 1 meningiomas, 498 with GTR and 133 with STR, and 101 WHO grade 2 meningiomas with GTR. The median follow-up was 4.6 years, the local recurrence rate was 12.0% and the rate of death was 8.4%. The biomarker classified 51.5% of meningiomas as intermediate risk and 9.6% as high risk. Combining the biomarker with extent of resection identified 19.7% as unfavorable (intermediate molecular risk with STR or high molecular risk), including 7.4% of newly diagnosed WHO grade 1 meningiomas with GTR. The risk score was prognostic for LFFR overall (hazard ratio per 0.1 increase in risk score 1.89, 95% confidence interval 1.58-2.25) and across WHO grades, extents of resection, and newly diagnosed or recurrent settings. Gene expression risk groups were prognostic for LFFR, with improved outcomes among low molecular risk compared to intermediate molecular risk (Log-rank, p=0.0002) and high molecular risk meningiomas (Log-rank, p<0.0001). These data suggest that a targeted gene expression biomarker can identify low grade meningiomas that are more likely to recur after surgery, possibly changing management for approximately one-fifth of cases.
EPID-09. THE NATURAL HISTORY AND MOLECULAR ARCHITECTURE OF INCIDENTAL MENINGIOMAS
Mirchia, Kanish , Raleigh, David R. , Nguyen, Minh , Chen, William C. , Magill, Stephen T. , Morshed, Ramin A.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii139-viii139

10.1093/neuonc/noae165.0545 Get It

Abstract The prevalence of asymptomatic, incidental meningiomas is increasing due to greater frequency of brain imaging. This retrospective cohort study of adult patients presenting at a single institution from 1996-2020 integrated clinical data, serial magnetic resonance imaging (MRI) volumetrics, DNA methylation profiling, and targeted gene expression profiling to define the natural history and molecular architecture of incidental meningiomas. Volumetrics were calculated from contrast-enhanced brain MRIs at time of diagnosis compared to serial surveillance MRIs (average 3 MRIs per patient pre-intervention, range: 1-12) DNA methylation groups and gene expression risk scores were defined for 123 samples that underwent resection. Time-to-event analyses were performed for progression-free survival (PFS), symptom-free survival (SFS), and treatment-free survival (TFS). The cohort included 238 meningiomas from 207 patients. Median age at diagnosis was 59 years and 81.5% of patients were female. Median clinical and imaging follow-up were 9.1 and 6.7 years, respectively, during which time 50.8% progressed. Median maximum diameter and volume at diagnosis were 2.20 cm and 4.25 cm3, respectively, and median pre-treatment volumetric growth rate was 19.2% per year. Median pre-treatment PFS and TFS were 3.10 and 1.27 years, respectively, and median SFS and post-treatment PFS were not reached. Cox proportional hazards regression identified maximum diameter at diagnosis as a significant predictor of worse pre-treatment PFS (multivariate HR 1.65 per 1 cm [95% CI 1.19–2.28], p=0.0027) and worse TFS (multivariate HR 1.44 per 1 cm [95% CI 1.17–1.76], p<0.001). Skull base tumors had with worse SFS (multivariate HR 2.48 [95% CI 1.02–6.00], p=0.045). Molecular and histological features among incidental meningiomas that ultimately underwent resection (n=176, 74.0%) were reassuring (89.2% WHO grade 1, 10.2% WHO grade 2). These findings suggest maximum diameter at diagnosis of incidental meningiomas is significantly associated with earlier progression and eventual treatment, and skull base tumors have earlier symptom development.
Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology
Walsh, Thomas J. , Ahmed, Sarah , Alastruey‐Izquierdo, Ana , Arendrup, Maiken Cavling , Borman, Andrew M. , Colgrove, Robert C. , Cornely, Oliver A. , Filkins, Laura , Groll, Andreas H. , Haase, Gerhard , Hubka, Vít , Kwon-Chung, June , Song, Yinggai , Vilela, Rachel, Vitale, Roxana G. , Wengenack, Nancy L. , de Hoog, Sybren , Walsh, Thomas J , Alastruey-Izquierdo, A , Arendrup, Maiken Cavling , Borman, Andrew , Filkins, Laura , Gené, Josepa , Groll, Andreas H , Hoenigl, Martin , Kidd, Sarah E , Kus, Julianne V , Kwon-Chung, Kyung J , Lockhart, Shawn R. , Meis, Jacques F , Mendoza, Leonel , Nguyen, M Hong , Vitale, Roxana G , Wengenack, Nancy L , White, Lewis , Zhang, Sean X , Cornely, Oliver A , Ahmed, Sarah A , Chen, Wen , Chowdhary, Anuradha , Denning, David W. , Dufresne, Philippe J. , Gangneux, Jean‐Pierre , Guillot, Jacques , Halliday, Catriona , Hawksworth, David L. , Hay, Roderick J. , Hoenigl, Martin , Jagielski, Tomasz , Kandemir, Hazal , Kidd, Sarah , Kus, Julianne V. , Kwon‐Chung, June , Meyer, Wieland , Song, Yinggai , Sorrell, Tania Christine , Stielow, J. Benjamin , Ostrosky‐Zeichner, Luis , Zhang, Sean X.

Mayo Clinic

Journal of Clinical Microbiology | November 11, 2024 | Volume: 62 | Issue: 12 | Pages: No page available

10.1128/jcm.00937-24 | PMID 39526838 Get It

ABSTRACT Medically important pathogenic fungi invade vertebrate tissue and are considered primary when part of their nature life cycle is associated with an animal host and are usually able to infect immunocompetent hosts. Opportunistic fungal pathogens complete their life cycle in environmental habitats or occur as commensals within or on the vertebrate body, but under certain conditions can thrive upon infecting humans. The extent of host damage in opportunistic infections largely depends on the portal and modality of entry as well as on the host’s immune and metabolic status. Diseases caused by primary pathogens and common opportunists, causing the top approximately 80% of fungal diseases [D. W. Denning, Lancet Infect Dis, 24:e428–e438, 2024, https://doi.org/10.1016/S1473-3099(23)00692-8 ], tend to follow a predictive pattern, while those by occasional opportunists are more variable. For this reason, it is recommended that diseases caused by primary pathogens and the common opportunists are named after the etiologic agent, for example, histoplasmosis and aspergillosis, while this should not be done for occasional opportunists that should be named as [causative fungus] [clinical syndrome], for example, Alternaria alternata cutaneous infection. The addition of a descriptor that identifies the location or clinical type of infection is required, as the general name alone may cover widely different clinical syndromes, for example, “rhinocerebral mucormycosis.” A list of major recommended human and animal disease entities (nomenclature) is provided in alignment with their causative agents. Fungal disease names may encompass several genera of etiologic agents, consequently being less susceptible to taxonomic changes of the causative species, for example, mucormycosis covers numerous mucormycetous molds.
Pig-to-human lung xenotransplantation in a brain-dead human recipient
Liu, Xiaoyou , Peng, Guilin, Shi, Jiang , Ju, Chunrong, He, Ping , Liu, Xiaoqing , Zhang, Zuopen, Chen, Chuanbao, Pan, Dengke, Yang, Zifeng , Guan, Wenda, 陈, 中华克劳斯, Liu, Menyang, Liang, Hengrui , Zhao, Yi , Huang, Weiqing , Rucker, A. Justin , Xu, Xin , He, Jianxing , Yang, Chao , Liu, Hui, Liu, Xiaoqing, Zhang, Zuopeng , Pan, Dengke , Yang, Zifeng , Guang, Wenda, Li, Hongtao , Chen, Zhonghua, Liang, Hengrui , Jeon, Kyeongman , Chen-Yoshikawa, Toyofumi Fengshi , Lal, Amos, Zhang, Kang , Zhang, Kang , Liu, Xiaoyou , Xu, Xin

Mayo Clinic

No container title available | November 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5155123/v1 Get It

Abstract This study reports the first pig-to-human lung xenotransplantation using a six gene-edited pig lung. A left lung from a gene-edited Chinese Bama Xiang pig was transplanted into a 39-year-old brain-dead human recipient. The xenograft maintained viability and functionality for 216 hours without signs of hyperacute rejection. Postoperatively, severe edema resembling primary graft dysfunction (PGD) was observed, potentially due to ischemia-reperfusion injury. Antibody-mediated rejection appeared to contribute to xenograft damage on postoperative days 3 and 6, with partial recovery by day 9 under the current immunosuppressive regimen. This pioneering study suggests that genetically modified pig lungs could potentially be used for future clinical applications in xenotransplantation.
Magnetic Resonance Elastography Combined With PI‐RADS v2.1 for the Identification of Clinically Significant Prostate Cancer
Chen, Jie , Chen, Yuntian , Deng, Liping , Tang, Hehan , Zhang, Zhen , Chen, Tingyu , Zeng, Hao , Yuan, Enyu , Yao, Jin , Song, Bin , Yao, Jin , Chen, Guoyong , Yuan, Yuan , Yin, Meng , Chen, Jun

Mayo Clinic

Journal of Magnetic Resonance Imaging | November 8, 2024 | Volume: 61 | Issue: 5 | Pages: 2248-2257

10.1002/jmri.29653 | PMID 39513399 Get It

BackgroundMultiparametric MRI may cause overdiagnosis of clinically significant prostate cancer (csPCa) with the Prostate Imaging Reporting and Data System version 2.1 (PI‐RADS v2.1).ObjectivesTo investigate the diagnostic performance of stiffness as a standalone and complementary marker to PI‐RADS v2.1 for diagnosing csPCa.Study TypeProspective.SubjectsOne hundred forty‐seven participants with pathologically confirmed prostate lesions (≥1 cm), including 71 with csPCa.Field Strength/SequenceT1‐weighted fast spin‐echo, T2‐weighted fast spin‐echo, single‐shot echo‐planar diffusion‐weighted imaging, fast 3D gradient‐echo T1‐weighted dynamic contrast‐enhanced imaging, and 3D single‐shot spin‐echo based echo‐planar MR elastography at 3.0 T.AssessmentThe PI‐RADS v2.1 score was assessed by three radiologists independently. Lesion shear stiffness (SS) values at 60 Hz and 90 Hz were measured. A modified PI‐RADS integrating stiffness with PI‐RADS v2.1 was developed. Diagnostic performance for csPCa was compared between stiffness, PI‐RADS v2.1 and the modified PI‐RADS.Statistical TestSpearman's correlation, Fleiss κ and intraclass correlation, Pearson correlation, one‐way analysis of variance, area under the receiver operating characteristic curve (AUC), and the Delong test. Significance level was P < 0.05.ResultsIn the peripheral zone, csPCa (N = 35) had significantly higher SS than non‐csPCa at 60 Hz (3.22 ± 0.66 kPa vs. 2.56 ± 0.56 kPa) and at 90 Hz (5.64 ± 1.30 kPa vs. 4.48 ± 0.84 kPa). PI‐RADS v2.1 showed 100% sensitivity, 58% specificity, and 0.79 AUC for detecting csPCa. SS achieved 97% sensitivity, 52% specificity, and 0.80 AUC at 60 Hz, while SS had 63% sensitivity, 87% specificity, and 0.78 AUC at 90 Hz. The modified PI‐RADS, combing SS at 60 Hz with PI‐RADS v2.1, resulted in a significantly increased AUC (0.86) compared to that of PI‐RADS v2.1, with a sensitivity of 97% and specificity of 75%.Data ConclusionStiffness can help identifying csPCa in the peripheral zone. Combining stiffness with the PI‐RADS v2.1 improved the diagnostic accuracy and specificity for csPCa.Evidence Level1Technical EfficacyStage 2
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial
Hubers, Scott , Benike, Sherry L., Johnson, Bradley K. , Scott, Christopher G. , Chen, Horng H. , Hubers, Scott A , McKie, Paul M , Scott, Christopher , Chen, Horng , McKie, Paul M.

Mayo Clinic

Circulation: Heart Failure | November 8, 2024 | Volume: 17 | Issue: 12 | Pages: No page available

10.1161/circheartfailure.124.011761 | PMID 39513267 Get It

BACKGROUND: Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF. METHODS: This open-label study included 67 patients hospitalized with acute HF and renal dysfunction. Patients were randomized to standard care, low-dose intravenous BNP (0.005 µg/kg per minute), or combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours. The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours. RESULTS: Treatment with BNP and BNP/PDEV inhibitor significantly increased plasma cGMP at 24 hours (+25.6% [+9.8%, +84.7%] and +60.8% [+32.3%, +103.8%] for BNP and BNP/PDEV versus −13.5% [−29.1%, +14.2%] with standard care; P =0.001). However, there was no significant change in estimated glomerular filtration rate 0 (−10.8%, +12.7%) for standard care versus 0 (−15.3%, +11.8%) for the BNP group versus –8.8% (−14.3%, +8.3%) for the BNP/PDEV group ( P =0.60) or blood urea nitrogen −1.4% (−10.7%, +12.0%) for standard care versus –5.9% (−14.6%, +9.4%) for the BNP group versus +6.9% (−5.3%, +18.8%) for the BNP/PDEV group ( P =0.38) between groups. Hypotension was more common in the BNP/PDEV inhibitor group. CONCLUSIONS: BNP and combination BNP/PDEV inhibition increased plasma cGMP in patients with acute HF but did not improve renal function or urinary sodium/cGMP excretion. Our study does not support the use of intravenous low-dose BNP with or without PDEV inhibition to enhance renal function in patients admitted with acute HF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00972569.
The Association Between Perioperative Red Blood Cell Transfusions and 1-Year Mortality After Major Cancer Surgery: An International Multicenter Observational Study
Ramirez, María F. , Chen, Lee‐lynn , Guzman, Luis Felipe Cuellar, Lobo, Francisco , Uribe‐Marquez, Santiago, Ruscic, Katarina J. , Chew, Sophia Tsong Huey , Lanigan, Megan , Investigators, On behalf of the ARCA-1, Cata, Juan P. , Guerra-Londoño, Juan Jose , Warner, Matthew A. , Huang, Jeffrey Jianhong , Investigators, On behalf of the ARCA-1

Mayo Clinic

Anesthesia & Analgesia | November 6, 2024 | Volume: 140 | Issue: 4 | Pages: 782-794

10.1213/ane.0000000000007236 | PMID 39504267 Get It

BACKGROUND: Packed red blood cell (pRBC) transfusions in patients undergoing surgery for cancer are given to treat anemia or acute hemorrhage. Evidence indicates that pRBC transfusions are associated with poor perioperative and oncological outcomes. The ARCA-1 (Perioperative Care in the Cancer Patient-1) study was designed to test the association between perioperative pRBC transfusions and postoperative morbidity and mortality in patients undergoing cancer surgery. The primary hypothesis of our study was that perioperative pRBC transfusions have a negative impact on postoperative morbidity and 1-year mortality. METHODS: ARCA-1 was an international multicenter prospective observational cohort study. Participating centers enrolled a minimum of 30 consecutive adult patients with cancer who underwent surgery with curative intent. The primary end point was all-cause mortality 1 year after major cancer surgery. Secondary end points were rates of perioperative blood product use, 1-year cancer-specific mortality, overall survival, and 30-day morbidity and mortality. We performed a propensity score matching analysis to adjust for selection bias. A multivariable logistic regression model was fitted to estimate the effects of significant covariates on 1-year mortality, cancer-related mortality, and overall survival. RESULTS: A total of 1079 patients were included in the study. The rate of perioperative pRBC transfusions was 21.1%. Preoperative comorbidities, including anemia, American Society of Anesthesiologists (ASA) score of III to IV, a history of coronavirus disease 2019 (COVID-19), myocardial infarction, stroke, need for dialysis, history of blood transfusions, and metastatic disease were statistically significantly more frequent in transfused patients compared to nontransfused patients. The 1-year mortality rate was higher in transfused patients before (19.7% vs 6.5%; P < .0001) and after (17.4% vs 13.2%; P = .29) propensity score matching. 1-year mortality was 1.97 times higher in transfused than in no-transfused patients (odd ratio [OR], 1.97; 95% confidence interval [CI], 1.13–3.41). The odds of 1-year cancer mortality for patients who had perioperative pRBCs was 1.82 times higher (OR, 1.82; 95% CI, 0.97–3.43) compared to those who did not receive perioperative pRBC transfusion. The effect of perioperative pRBC transfusion on overall survival was also significant (hazard ratio [HR], 1.85; 95% CI, 1.15–2.99). Transfused patients also had a higher rate of 30-day postoperative mortality before (3.5% vs 0.7%; P = .0009) and after propensity score matching (4.2% vs 1.8%; P = .34). CONCLUSIONS: This international, multicenter observational study showed that perioperative pRBC transfusion was associated with an increased mortality risk.
791 Immunological correlates of response to vismodegib and PD-1 blockade in an autochthonous model of basal cell nevus (Gorlin-Goltz) syndrome
Ager, Casey R. , Zhu, Yucui, Chen, Dana, Athar, Mohammed, Izar, Benjamin , Bickers, David R., Jugler, Collin , Chen, Dana, Kim, Arianna L.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A896-A896

10.1136/jitc-2024-sitc2024.0791 Get It

653 Phase I/II clinical trial for radiation and dendritic cell combination immunotherapy in patients with unresectable hepatocellular carcinoma and cholangiocarcinoma
Wu, Chen , Fonkoua, Lionel Aurelien Kankeu , Wang, Panwen , Hallemeier, Christopher L. , Atwell, Thomas D. , Bornschlegl, Svetlana, Martinez, Kodi, McCoy, Gabrielle, Regan, Kevin M., Shao, Zuoyi , Li, Ying , Hallemeier, Christopher Leigh , Tran, Nguyen, Wang, Junwen , Zhang, Henan , Dietz, Allan B. , Dong, Haidong , Park, Sean S. , Yi, Lin , Roberts, Lewis R.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A749-A750

10.1136/jitc-2024-sitc2024.0653 Get It